# LIFEVANTAGE CORP (LFVN) · Edgar & Edgarette company card

> Lifevantage (LFVN) saw revenue fall 20.1% in FY2026 to $183 million, operating margin 3.3% against a -3.8% median for pharmaceutical preparations, equity 54.1% of assets, and dividend per share up 1 year running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 849146 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/LFVN) · [JSON](https://www.pops4.com/boards/company/LFVN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $183M |
| Revenue growth, 1 year | -20.1% |
| Revenue growth per year | -3.0% |
| Operating margin | 3.3% (prior year 5.3%) |
| Net margin | 2.8% |
| Operating cash flow | $10M |
| Capital spending | $4M |
| Free cash flow | $7M |
| Cash | $15M |
| Long-term debt | — |
| Total assets | $62M |
| Total equity | $34M |
| Equity ÷ assets | 54.1% |
| Return on equity | 15.1% |
| Dividend per share | $0.185 |
| Dividend years rising | 1 |

## Readings, computed from those figures

- Altman Z: -1.63 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.73 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Steady earner · steady and paying a dividend, with average cash

## Edgarette's reading

Exposure: revenue $182.6M (FY2026). Experience: revenue down 20.1% on the year, down 3.0% a year over 4 years; operating margin 3.3%, down from 5.3%. Soundness: equity 54.1% of assets, return on equity 15.1%, payout 46.2% of profit, dividend per share up 1 year running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $128.5M and $190.8M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $116.3M to $211.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 3.3% against a -3.8% median; growth -20.1% against 13.7%.

Range logged 2026-09-24, receipt 9fabdb7db29bb200, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-08-03 ([filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526330531/0001193125-26-330531-index.htm))

## Recent filings

- 8-K · filed 2026-10-05 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526414122/0001193125-26-414122-index.htm)
- DEF 14A · filed 2026-09-18 · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526395513/0001193125-26-395513-index.htm)
- 8-K · filed 2026-08-27 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526371265/0001193125-26-371265-index.htm)
- 10-K · filed 2026-08-27 · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526371257/0001193125-26-371257-index.htm)
- 8-K · filed 2026-08-03 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526330531/0001193125-26-330531-index.htm)
- 8-K · filed 2026-05-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/849146/000119312526208934/0001193125-26-208934-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000849146.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=849146

## Cite

POPS4, Edgar & Edgarette: LIFEVANTAGE CORP (LFVN) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/LFVN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.